Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
出版年份 2017 全文链接
标题
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
作者
关键词
MAPK signaling cascades, ERK signaling cascade, Cancer treatment, Non-small cell lung cancer, Signal inhibition, Ras signaling, Oncogenic signaling, Signal processing
出版物
PLoS One
Volume 12, Issue 10, Pages e0185862
出版商
Public Library of Science (PLoS)
发表日期
2017-10-06
DOI
10.1371/journal.pone.0185862
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
- (2016) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
- (2016) H. Kitai et al. Cancer Discovery
- Signal Transduction in Cancer
- (2015) R. Sever et al. Cold Spring Harbor Perspectives in Medicine
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- The role of MEK inhibitors in the treatment of metastatic melanoma
- (2014) Antonio M. Grimaldi et al. CURRENT OPINION IN ONCOLOGY
- Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
- (2014) M. R. Junttila et al. MOLECULAR CANCER THERAPEUTICS
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma
- (2014) Vito W. Rebecca et al. Pigment Cell & Melanoma Research
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- MEK in cancer and cancer therapy
- (2013) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Automatic Nuclei Segmentation in H&E Stained Breast Cancer Histopathology Images
- (2013) Mitko Veta et al. PLoS One
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals
- (2012) John G. Albeck et al. MOLECULAR CELL
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
- (2010) Christophe Frémin et al. Journal of Hematology & Oncology
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
- (2010) Mallika Singh et al. NATURE BIOTECHNOLOGY
- The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
- (2010) O. E. Sturm et al. Science Signaling
- Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway
- (2009) S.-Y. Shin et al. JOURNAL OF CELL SCIENCE
- Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
- (2009) D. A. Ritt et al. MOLECULAR AND CELLULAR BIOLOGY
- Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy
- (2008) B. B. Friday et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation